Immunome (Nasdaq:IMNM) - Cotización, noticias y análisis

Resumen de acción IMNM

Immunome, Inc. es una empresa biotecnológica que desarrolla terapias específicas contra el cáncer.

IMNM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 55.51%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Immunome, Inc.

Arcutis Biotherapeutics

NasdaqGS:ARQT

US$900.6m

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

Praxis Precision Medicines

NasdaqGS:PRAX

US$674.1m

Taysha Gene Therapies

NasdaqGS:TSHA

US$731.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Immunome
Historical stock prices
Current Share Price	US$16.00
52 Week High	US$30.96
52 Week Low	US$5.20
Beta	1.85
1 Month Change	2.50%
3 Month Change	-28.70%
1 Year Change	203.03%
3 Year Change	-5.66%
5 Year Change	n/a
Change since IPO	18.96%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	IMNM	US Biotechs	Mercado US
7D	2.9%	0.2%	1.0%
1Y	203.0%	8.4%	21.8%

Rentabilidad vs. Industria: IMNM superó al sector US Biotechs , que obtuvo un rendimiento del -2.3% el año pasado.

Rentabilidad vs. Mercado: IMNM superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.

Volatilidad de los precios

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	8.4%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.8%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	2.9%

Precio estable de las acciones: El precio de las acciones de IMNM ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IMNM (10%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	62	Clay Siegall	immunome.com

Immunome, Inc, empresa de biotecnología, desarrolla terapias dirigidas contra el cáncer. El activo clínico de la empresa comprende AL102, un inhibidor de la gamma secretasa en fase de investigación actualmente en evaluación en un ensayo de fase 3 para el tratamiento de tumores desmoides; y los activos preclínicos consisten en IM-1021, un receptor huérfano 1 similar a la tirosina quinasa y conjugados anticuerpo-fármaco, así como IM-3050, una terapia radioligando dirigida a la proteína de activación de fibroblastos; e IM-4320, un candidato a inmunoterapia anti-IL-38. Immunome, Inc. se constituyó en 2006 y tiene su sede en Bothell, Washington.

Resumen de fundamentos de Immunome, Inc.

¿Cómo se comparan los beneficios e ingresos de Immunome con su capitalización de mercado?
Estadísticas fundamentales de IMNM
Capitalización bursátil	US$941.51m
Beneficios(TTM)	-US$232.03m
Ingresos (TTM)	US$12.68m

75.7x

Ratio precio-ventas (PS)

-4.1x

Ratio precio-beneficio (PE)

¿Está IMNM sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMNM
Ingresos	US$12.68m
Coste de los ingresos	US$34.38m
Beneficio bruto	-US$21.70m
Otros gastos	US$210.33m
Beneficios	-US$232.03m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.87
Margen bruto	-171.08%
Margen de beneficio neto	-1,829.44%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IMNM a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IMNM

Recompensas

Análisis de riesgos

Competidores de Immunome, Inc.

NasdaqGS:ARQT

US$900.6m

NasdaqCM:PNT

US$1.3b

NasdaqGS:PRAX

US$674.1m

NasdaqGS:TSHA

US$731.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Recent updates

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01